Is DARE or GRI more profitable?

GRI Bio has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. GRI Bio's return on equity of -134.03% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience -803.80% -748.30% -38.75% GRI Bio N/A -134.03% -106.83%

Do analysts recommend or GRI?

GRI Bio has a consensus target price of $21.00, suggesting a potential upside of 1,400.00%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts clearly believe GRI Bio is more favorable than . Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GRI Bio 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings and valuation, or GRI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio N/A N/A N/A N/A N/A GRI Bio N/A N/A -$11.96M -$38.37 N/A

Is or GRI more profitable?

's return on equity of 0.00% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets N/A N/A N/A GRI Bio N/A -134.03% -106.83%

Which has better valuation & earnings, GRI or CLRB?

Cellectar Biosciences is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRI Bio N/A N/A -$11.96M -$38.37 N/A Cellectar Biosciences N/A N/A -$21.79M -$3.84 N/A

Is GRI or CLRB more profitable?

GRI Bio's return on equity of -134.03% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -134.03% -106.83% Cellectar Biosciences N/A -185.35% -115.42%

Is TVRD or GRI more profitable?

GRI Bio's return on equity of -134.03% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -145.40% -91.11% GRI Bio N/A -134.03% -106.83%

GRI Bio (GRI) Competitors

$1.41 +0.01 (+0.71%)

As of 04:00 PM Eastern

Compare

GRI vs. DARE, CYCN, CLRB, KPTI, and TVRD

Should you buy GRI Bio stock or one of its competitors? GRI Bio's main competitors and comparable companies include Dare Bioscience (DARE), Cyclerion Therapeutics (CYCN), Cellectar Biosciences (CLRB), Karyopharm Therapeutics (KPTI), and Tvardi Therapeutics (TVRD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does GRI Bio compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and GRI Bio (NASDAQ:GRI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

GRI Bio has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. GRI Bio's return on equity of -134.03% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
GRI Bio	N/A	-134.03%	-106.83%

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 3.4% of Dare Bioscience shares are owned by company insiders. Comparatively, 0.6% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

GRI Bio has lower revenue, but higher earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.37M	10.50	-$13.40M	-$0.70	N/A
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A

Dare Bioscience has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, GRI Bio has a beta of -1.21, suggesting that its stock price is 221% less volatile than the broader market.

In the previous week, Dare Bioscience had 4 more articles in the media than GRI Bio. MarketBeat recorded 6 mentions for Dare Bioscience and 2 mentions for GRI Bio. GRI Bio's average media sentiment score of 1.39 beat Dare Bioscience's score of 0.31 indicating that GRI Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Dare Bioscience	Neutral
GRI Bio	Positive

Dare Bioscience presently has a consensus target price of $6.50, indicating a potential upside of 791.63%. GRI Bio has a consensus target price of $21.00, indicating a potential upside of 1,400.00%. Given GRI Bio's higher probable upside, analysts plainly believe GRI Bio is more favorable than Dare Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Dare Bioscience and GRI Bio tied by winning 6 of the 12 factors compared between the two stocks.

How does GRI Bio compare to ?

(:) and GRI Bio (NASDAQ:GRI) are related companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

's return on equity of 0.00% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
	N/A	N/A	N/A
GRI Bio	N/A	-134.03%	-106.83%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
	N/A	N/A	N/A	N/A	N/A
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A

GRI Bio has a consensus target price of $21.00, suggesting a potential upside of 1,400.00%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts clearly believe GRI Bio is more favorable than .

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

34.0% of GRI Bio shares are owned by institutional investors. 0.6% of GRI Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, had 1108 more articles in the media than GRI Bio. MarketBeat recorded 1110 mentions for and 2 mentions for GRI Bio. GRI Bio's average media sentiment score of 1.39 beat 's score of 0.00 indicating that GRI Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
	Neutral
GRI Bio	Positive

Summary

GRI Bio beats on 6 of the 9 factors compared between the two stocks.

How does GRI Bio compare to Cellectar Biosciences?

GRI Bio (NASDAQ:GRI) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

GRI Bio presently has a consensus price target of $21.00, suggesting a potential upside of 1,400.00%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 832.20%. Given GRI Bio's higher possible upside, equities analysts clearly believe GRI Bio is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, GRI Bio had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 2 mentions for GRI Bio and 1 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 1.79 beat GRI Bio's score of 1.39 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
GRI Bio	Positive
Cellectar Biosciences	Very Positive

GRI Bio has a beta of -1.21, indicating that its share price is 221% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 0.6% of GRI Bio shares are owned by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cellectar Biosciences is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

GRI Bio's return on equity of -134.03% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-134.03%	-106.83%
Cellectar Biosciences	N/A	-185.35%	-115.42%

Summary

Cellectar Biosciences beats GRI Bio on 7 of the 13 factors compared between the two stocks.

How does GRI Bio compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and GRI Bio (NASDAQ:GRI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

GRI Bio has lower revenue, but higher earnings than Karyopharm Therapeutics. GRI Bio is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.05	-$196.04M	-$13.09	N/A
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A

In the previous week, GRI Bio had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 2 mentions for GRI Bio and 1 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.82 beat GRI Bio's score of 1.39 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Karyopharm Therapeutics	Very Positive
GRI Bio	Positive

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 0.6% of GRI Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Karyopharm Therapeutics presently has a consensus target price of $11.50, indicating a potential upside of 3,550.79%. GRI Bio has a consensus target price of $21.00, indicating a potential upside of 1,400.00%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than GRI Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

GRI Bio has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
GRI Bio	N/A	-134.03%	-106.83%

Karyopharm Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, GRI Bio has a beta of -1.21, suggesting that its share price is 221% less volatile than the broader market.

Summary

Karyopharm Therapeutics beats GRI Bio on 11 of the 15 factors compared between the two stocks.

How does GRI Bio compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and GRI Bio (NASDAQ:GRI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

GRI Bio's return on equity of -134.03% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
GRI Bio	N/A	-134.03%	-106.83%

Tvardi Therapeutics presently has a consensus price target of $9.40, indicating a potential upside of 840.00%. GRI Bio has a consensus price target of $21.00, indicating a potential upside of 1,400.00%. Given GRI Bio's higher possible upside, analysts clearly believe GRI Bio is more favorable than Tvardi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Tvardi Therapeutics had 3 more articles in the media than GRI Bio. MarketBeat recorded 5 mentions for Tvardi Therapeutics and 2 mentions for GRI Bio. GRI Bio's average media sentiment score of 1.39 beat Tvardi Therapeutics' score of 0.72 indicating that GRI Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Tvardi Therapeutics	Positive
GRI Bio	Positive

GRI Bio has lower revenue, but higher earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	1.87	-$18.21M	-$2.79	N/A
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by insiders. Comparatively, 0.6% of GRI Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tvardi Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, GRI Bio has a beta of -1.21, indicating that its stock price is 221% less volatile than the broader market.

Summary

Tvardi Therapeutics beats GRI Bio on 10 of the 14 factors compared between the two stocks.

Get GRI Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRI vs. The Competition

Export

Metric	GRI Bio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.06M	$12.65B	$7.43B	$12.93B
Dividend Yield	N/A	2.63%	2.52%	19.59%
P/E Ratio	-0.04	805.27	274.95	25.40
Price / Sales	N/A	839.52	568.69	75.42
Price / Cash	N/A	84.08	76.68	52.75
Price / Book	0.34	9.32	10.32	6.02
Net Income	-$11.96M	$2.83B	$3.49B	$380.68M
7 Day Performance	-16.67%	-3.46%	-2.55%	-3.01%
1 Month Performance	-23.08%	-7.30%	-6.88%	-5.59%
1 Year Performance	-97.51%	-5.48%	1.80%	-5.24%

GRI Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRI GRI Bio	3.5152 of 5 stars	$1.40 flat	$21.00 +1,400.0%	-97.4%	$3.06M	N/A	N/A	5	Analyst Forecast Short Interest Decrease
DARE Dare Bioscience	2.5967 of 5 stars	$0.83 -1.2%	$6.50 +680.2%	-64.6%	$16.58M	$1.03M	N/A	24
CYCN Cyclerion Therapeutics	N/A	$3.49 +3.9%	N/A	N/A	$16.33M	$2.07M	N/A	30	Gap Up High Trading Volume
CLRB Cellectar Biosciences	3.5622 of 5 stars	$1.51 -9.6%	$11.00 +628.5%	-76.3%	$15.78M	N/A	N/A	11	News Coverage Gap Up High Trading Volume
KPTI Karyopharm Therapeutics	3.5844 of 5 stars	$0.65 -3.1%	$11.50 +1,669.5%	-94.5%	$15.21M	$146.07M	N/A	228

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRI) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GRI Bio (GRI) Competitors

GRI vs. DARE, CYCN, CLRB, KPTI, and TVRD

How does GRI Bio compare to Dare Bioscience?

Summary

How does GRI Bio compare to ?

Summary

How does GRI Bio compare to Cellectar Biosciences?

Summary

How does GRI Bio compare to Karyopharm Therapeutics?

Summary

How does GRI Bio compare to Tvardi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRI vs. The Competition

GRI Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GRI Bio (GRI) Competitors

GRI vs. DARE, CYCN, CLRB, KPTI, and TVRD

How does GRI Bio compare to Dare Bioscience?

Is DARE or GRI more profitable?

Do institutionals and insiders believe in DARE or GRI?

Which has better valuation and earnings, DARE or GRI?

Which has more volatility & risk, DARE or GRI?

Does the media prefer DARE or GRI?

Do analysts recommend DARE or GRI?

Summary

How does GRI Bio compare to ?

Is or GRI more profitable?

Which has better earnings and valuation, or GRI?

Do analysts recommend or GRI?

Do insiders & institutionals have more ownership in or GRI?

Does the media prefer or GRI?

Summary

How does GRI Bio compare to Cellectar Biosciences?

Do analysts recommend GRI or CLRB?

Does the media favor GRI or CLRB?

Which has more volatility and risk, GRI or CLRB?

Do insiders and institutionals have more ownership in GRI or CLRB?

Which has better valuation & earnings, GRI or CLRB?

Is GRI or CLRB more profitable?

Summary

How does GRI Bio compare to Karyopharm Therapeutics?

Which has stronger earnings and valuation, KPTI or GRI?

Does the media prefer KPTI or GRI?

Do insiders & institutionals hold more shares of KPTI or GRI?

Do analysts recommend KPTI or GRI?

Is KPTI or GRI more profitable?

Which has more risk & volatility, KPTI or GRI?

Summary

How does GRI Bio compare to Tvardi Therapeutics?

Is TVRD or GRI more profitable?

Do analysts recommend TVRD or GRI?

Does the media refer more to TVRD or GRI?

Which has preferable earnings & valuation, TVRD or GRI?

Do institutionals and insiders believe in TVRD or GRI?

Which has more volatility & risk, TVRD or GRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRI vs. The Competition

GRI Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools